Claims for Patent: 9,447,176

Summary for Patent: 9,447,176

Title:	Methods and compositions for treating complement-associated disorders
Abstract:	The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
Inventor(s):	Rother; Russell P. (Oklahoma City, OK), Bedrosian; Camille (Woodbridge, CT), Squinto; Stephen P. (Bethany, CT), Bell; Leonard (Woodbridge, CT)
Assignee:	Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:	13/128,523
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,447,176
Patent Claims:	1. A method for treating atypical hemolytic uremic syndrome (aHUS), the method comprising administering to a patient in need thereof eculizumab in an amount effective to treat aHUS in the patient; wherein the eculizumab is intravenously administered to the patient under the following schedule: at least 600 mg of eculizumab once per week for four consecutive weeks; and beginning at week five, maintenance doses of at least 900 mg eculizumab every two weeks thereafter. 2. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain at least 50 .mu.g of eculizumab per milliliter of the patient's blood. 3. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain at least 100 .mu.g of eculizumab per milliliter of the patient's blood. 4. The method of claim 1, wherein the eculizumab is administered to the patient in an amount and with a frequency to maintain a concentration of at least 0.7 molecules of eculizumab per every C5 molecule in the patient's blood.

Details for Patent 9,447,176

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	03/16/2007		2028-11-10